How ICER Underestimates High Cholesterol

The Institute for Clinical and Economic Review claims that new medications for high cholesterol aren’t worth their cost. The economists overlook the needs of high-risk patients – and underestimate the impact of high cholesterol.

View Graphic

Tags:

Categorized in: